Infectious Diseases News and Research

RSS

RPCI researcher receives grant to explore link between race and breast cancer

Christine Ambrosone, MD, Chair of Cancer Prevention and Control at Roswell Park Cancer Institute (RPCI), has received a grant for $165,000 from the Breast Cancer Research Foundation to study the possible link between race and the possibility of being diagnosed with aggressive breast cancers.

3 Apr 2010

Researchers explore microbial infection of human cells in space environment

In a first-of-its-kind experiment, the unique conditions of spaceflight will be used to examine how cells remain healthy or succumb to disease, particularly in the face of stress or damage.

3 Apr 2010

Recent releases in Global Health

"Achieving the [Millennium Development Goal] MDG 4 target of reducing newborn and child mortality will require concerted efforts to scale up evidence-based interventions, especially community-based preventive and therapeutic strategies in primary care," according to a Lancet comment that reflects on the challenges associated with developing "the appropriate mix of strategies" to improve maternal health.

3 Apr 2010

Utilizing "synthetic population" in simulating spread of infectious outbreaks

Did you know that filling out your census card will help computer scientists model how diseases spread in the United States?

2 Apr 2010

Sunshine vitamin cures common health problems

What do obesity, heart disease, depression, diabetes, and fibromyalgia have in common? The answer is vitamin D deficiency. More than 200 million Americans lack this essential vitamin and as a result suffer from a host of daily annoyances, chronic conditions, and even life-threatening illnesses.

2 Apr 2010

Bloomberg examines potential benefits, drawbacks to PrEP

"Gilead Sciences Inc. may learn this year whether its drugs for treating HIV can also stop people from catching the virus in the first place," Bloomberg writes in a piece that examines the potential benefits and drawbacks to using low-doses of HIV/AIDS medications to reduce a person's risk of becoming infected with HIV. According to the news service, the initial results of 10 trials including more than 20,000 people could be available as early as July.

2 Apr 2010

PolyMedix secures $14M credit facility with Hercules Technology II

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has secured a $14 million credit facility with Hercules Technology II, L.P., an affiliate of Hercules Technology Growth Capital, Inc.

1 Apr 2010

Soligenix's revenues for 2009 increase by 22%

Soligenix, Inc., a late-stage biopharmaceutical company, today announced its financial results for 2009.

1 Apr 2010

VA may expand list of Gulf War illnesses

The Army Times/Veterans Today: "In a boost for veterans of the 1991 Persian Gulf War and those who have served in recent years in Iraq and Afghanistan, the Veterans Affairs Department has proposed changes to its list of illnesses that are presumed connected to service to include nine infectious diseases."

1 Apr 2010

GSK, Isis Pharmaceuticals collaborate to develop new therapeutics for rare and serious disease

GlaxoSmithKline and Isis Pharmaceuticals, Inc. announced today a new strategic alliance that will apply the Isis antisense drug discovery platform to seek out and develop new therapeutics against targets for rare and serious disease, including infectious diseases and some conditions causing blindness.

31 Mar 2010

PhRMA report: 234 medicines in development for special health care needs of children

America's pharmaceutical research and biotechnology companies are developing 234 medicines for the special health care needs of children, according to a new report released today by the Pharmaceutical Research and Manufacturers of America.

31 Mar 2010

PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic

PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.

31 Mar 2010

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

NovaBay Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported full-year and fourth quarter financial results for 2009. The company also highlighted recent progress of its proprietary and partnered development programs.

30 Mar 2010

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.

30 Mar 2010

Wall Street journal examines fundraising efforts by GAVI, Global Fund

The GAVI Alliance and the Global Fund to Fight AIDS, Tuberculosis and Malaria "on Friday began an effort to raise as much as $24 billion from members of the Group of 20 nations that will test whether a major push begun a decade ago against infectious diseases can survive the global recession," the Wall Street Journal reports. The two groups held meetings last week in The Hague with government representatives from existing and potential donor nations, according to the newspaper.

30 Mar 2010

Preclinical study of DAS181 for treatment and prevention of ILI published

NexBio, Inc. announced today the publication in the Journal of Infectious Diseases of a preclinical study suggesting that treatment with DAS181 (Fludase®) may reduce the risk of secondary bacterial pneumonia following influenza virus infection.

30 Mar 2010

Research challenges current thinking about TB bacterium

Two new tuberculosis studies by UT Southwestern Medical Center researchers provide good news and bad news about the bacterium that infects nearly a third of the world's population and a disease that kills nearly 2 million people each year.

30 Mar 2010

DIATHERIX GI test panel can detect nine types of GI infections

DIATHERIX Laboratories adds a gastrointestinal panel to its lineup of highly sensitive, rapid response diagnostic tests. In a single result, the DIATHERIX GI panel can detect and differentiate nine types of GI infections so physicians can quickly identify patients who have severe, life-threatening infections.

30 Mar 2010

Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced

Novavax, Inc. a clinical-stage vaccine company, released the final results from a Phase II clinical trial evaluating Novavax's trivalent seasonal influenza Virus-like particle (VLP) vaccine candidate in healthy adults. The study enrolled healthy volunteers 18 to 49 years in age who were immunized with a single injection of Novavax's trivalent seasonal influenza VLP vaccine matched to the influenza strains recommended for the 2008-2009 influenza vaccine.

29 Mar 2010